SWOG clinical trial number
S9626
A Phase III Trial of Placebo Versus Megestrol Acetate 20 mg/Day Versus Megestrol Acetate 40 mg/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer
100% Accrual
Accrual
100%
Closed
100% Accrual
Accrual
100%
Published
Abbreviated Title
Megestrol acetate (20 mg vs. 40 mg) vs. placebo
Treatment
Megestrol acetate
Stage T1-3, N0-1, M0 infiltrating breast cancer treated with appropriate local and regional therapy; pts w/DCIS are not eligible; ¤pts must have completed all primary therapy for breast cancer; pts taking tamoxifen must have started tamoxifen >= 4 months prior to randomization; pts must have never participated in any NCI sponsored adjuvant breast protocols; pts must have completed Patient Daily Log of Hot Flashes for 7 days prior to
randomization and must have recorded 10 or more hot flashes of any severity or 5 or more severe or very severe hot flashes; pt must not be pregnant; pts must not currently be on steroids or any other hormones except tamoxifen.
2008
A phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group study 9626 [PMID18375894 ]
JW Goodwin;SJ Green;CM Moinpour;JD Bearden III;JK Giguere;CS Jiang;SM Lippman;S Martino;KS Albain Journal of Clinical Oncology 26(10):1650-1656
2001
Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626
JW Goodwin;SJ Green;S Giarritta;JK Giguere;K Hoelzer;J Bearden;RB Livingston;J Gralow;PA Ganz;S Martino;KS Albain Breast Cancer Research and Treatment 69(3):292(#462)
